ArticleJournal of neuro-oncology2016
Age alone is not a predictor for survival in glioblastoma.
Article in Journal of neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM).Journal of neuro-oncology · 2024Trial
- Assessment of the RANO-resect criteria in elderly patients with glioblastoma.Journal of neuro-oncology · 2025Article
- Resilience and spiritual well-being as resources for coping with radiotherapy and surviving in patients with glioblastoma.Palliative & supportive care · 2024Observational
- A novel scoring system proposal to guide surgical treatment indications for high grade gliomas in elderly patients: DAK-75.Neurosurgical review · 2024Observational
- Predictive Model to Identify the Long Time Survivor in Patients with Glioblastoma: A Cohort Study Integrating Machine Learning Algorithms.Journal of molecular neuroscience : MN · 2024Article
- Pyrosequencing Analysis of O-6-Methylguanine-DNA Methyltransferase Methylation at Different Cut-Offs of Positivity Associated with Treatment Response and Disease-Specific Survival in Isocitrate Dehydrogenase-Wildtype Grade 4 Glioblastoma.International journal of molecular sciences · 2024Article
- Nitric Oxide Synthase Inhibition Prevents Cell Proliferation in Glioblastoma.Journal of molecular neuroscience : MN · 2023Article
- Preoperative neurocognitive function as an independent survival prognostic marker in primary glioblastoma.Neuro-oncology practice · 2023Article
- Mortality trends in primary malignant brain and central nervous system tumors vary by histopathology, age, race, and sex.Journal of neuro-oncology · 2023Article
- Siglec15 is a prognostic indicator and a potential tumor-related macrophage regulator that is involved in the suppressive immunomicroenvironment in gliomas.Frontiers in immunology · 2023Article
- Article
- Can Extended Chemotherapy Improve Glioblastoma Outcomes? A Retrospective Analysis of Survival in Real-World Patients.Journal of personalized medicine · 2022Article
- Radiotherapy for glioblastoma patients with poor performance status.Journal of cancer research and clinical oncology · 2022Article
- Treatment approach and survival from glioblastoma: results from a population-based retrospective cohort study from Western Norway.BMJ open · 2021Article
- Article
- Reoperation for recurrent glioblastomas: What to expect?Surgical neurology international · 2021Article
- Identification of an immune gene signature for predicting the prognosis of patients with uterine corpus endometrial carcinoma.Cancer cell international · 2020Article
- Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
- ＜Editors' Choice＞ Impact of maintenance of postoperative performance status on survival in elderly patients over 70 with high-grade astrocytoma.Nagoya journal of medical science · 2020Article
- Cognitive impairment three months after surgery is an independent predictor of survival time in glioblastoma patients.Journal of neuro-oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over half of glioblastoma (GBM) cases are diagnosed in patients older than 65 years. Their median overall survival (OS) is 4-5 months, compared with 12-14 months in patients younger than 70 years. This retrospective audit aims to identify patterns of care and survival of patients diagnosed with GBM at a single institution in Melbourne, Australia. Consecutive histological diagnoses of adult primary GBM from January 2010 to December 2012 were retrospectively identified from medical records. Demographic, treatment and survival characteristics were recorded until death, with follow-up to January 1st 2015. Survival was estimated by Kaplan-Meier method. Planned, sub-group analyses were conducted using multivariate Cox proportional hazards model to identify differences between elderly and younger cohorts, as well as ECOG. 165 patients were identified (36 % aged ≥70 years). Those ≥70 years had a poorer performance status (ECOG 3-4: 27 vs 10 %, p = .005); poorer median OS (2.6 vs 11.5 months, p < .001); and were less likely to receive adjuvant treatment (no treatment: 40 vs 16 %, p < .001) compared with patients <70 years. Age was not a significant predictor of poorer os (HR 1.0; 0.99-1.03; p > .05), after adjusting for other clinical factors. Significant predictors of poorer os were poor performance status (p = .001), bilateral tumours (p = .04), biopsy only (p = .001), and no adjuvant treatment (p < .001). In patients diagnosed with GBM, those older than 70 years often present with poor performance status, are less likely to receive adjuvant treatment and have inferior os compared with younger patients. Treatment recommendations should be based on performance status/fitness, not age alone.
Indexed as
Identifiers
27406585What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.